MEDIMMUNE RESPIGAM RSV TREATMENT INDICATION
Executive Summary
MEDIMMUNE RESPIGAM RSV TREATMENT INDICATION will be the next focus of the company's efforts to gain approval of the polyclonal antibody product, MedImmune indicated June 27. RespiGam (respiratory syncytial virus immune globulin) was rejected in December by FDA's Blood Products Advisory Committee as a prophylactic for RSV due to concerns about compromised data ("The Pink Sheet" Dec. 6, p. 6).